Kristen Aguirre, MD
Dermatology · Oceanside, CANPI 1205255288
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Biofrontera Inc. at 44.0% of the total. Reporting peaked in 2019 at $5,919 and has fallen 81.8% since, to $1,080 in 2025.
Across 275 payments — averaging $44.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biofrontera Inc.$5K
- AbbVie$762
- Lilly USA, LLC$670
- Johnson & Johnson$587
- Sanofi$577
- Galderma Laboratories, L.p.$562
- plus $4K from 29 others
Across 27 payments — averaging $3117.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma AS$41K
- Dr.reddy's Laboratories,inc.$25K
- Amgen$18K
What the payments were for
- Speaking & faculty fees$5,00041%
- Travel & lodging$190%
- Food & beverage$6,65655%
- Education$4674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biofrontera Inc. | 14 | $5,339 |
| AbbVie | 42 | $762 |
| Lilly USA, LLC | 25 | $670 |
| Johnson & Johnson | 14 | $587 |
| Sanofi | 17 | $577 |
| Galderma Laboratories, L.p. | 13 | $562 |
| LEO Pharma Inc. | 25 | $493 |
| Pfizer | 22 | $486 |
| Regeneron Healthcare Solutions, Inc. | 13 | $342 |
| Sun Pharmaceutical Industries Inc. | 7 | $248 |
| E.r. Squibb & Sons, L.L.C. | 8 | $247 |
| Dermavant Sciences, Inc. | 7 | $228 |
| Arcutis Biotherapeutics, Inc. | 5 | $216 |
| Amgen | 9 | $194 |
| Incyte Corporation | 8 | $176 |
| UCB, Inc. | 6 | $164 |
| Novartis | 5 | $91 |
| Janssen Scientific Affairs, LLC | 1 | $86 |
| Almirall LLC | 3 | $77 |
| EPI Health, LLC | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Boehringer Ingelheim | 2 | $60 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $58 |
| VYNE Pharmaceuticals Inc. | 3 | $57 |
| Merz North America, Inc. | 2 | $54 |
| Apyx Medical Corporation | 4 | $47 |
| Nabriva Therapeutics, PLC | 2 | $39 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $35 |
| DUSA Pharmaceuticals, Inc. | 1 | $24 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $20 |
| Sensus Healthcare, Inc. | 1 | $20 |
| Misonix Inc | 1 | $18 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $11 |
| Organon | 1 | $8 |
| Mayne Pharma Commercial LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,142 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 14 | $52,389 |
| Fluorouracil | 94 | $4,928 |
| Clobetasol Propionate | 49 | $2,440 |
| ValacyclovirValacyclovir Hcl | 39 | $2,255 |
| Fluocinonide | 52 | $2,195 |
| Metronidazole | 29 | $1,670 |
| Gentamicin Sulfate | 20 | $1,178 |
| Ketoconazole | 78 | $1,050 |
| Minoxidil | 100 | $928 |
| Clindamycin Phosphate | 25 | $774 |
| Fluocinolone Acetonide | 15 | $670 |
| Doxycycline Hyclate | 21 | $627 |
| Triamcinolone Acetonide | 39 | $504 |
| Hydrocortisone | 76 | $453 |
| Minocycline Hcl | 18 | $350 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Oceanside
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.